Rigel Pharmaceuticals Inc (RIGL) stock
RIGLNasdaqPharmaceutical PreparationsFiscal year ends December 31
$44.46−1.23 (-2.69%)
Close on Nov 13, 2026Market cap $830.51MP/E 2.9Yield –
Rigel Pharmaceuticals gross margin
Gross margin is gross profit as a percentage of revenue.
Rigel Pharmaceuticals's gross margin for the twelve months ending Sep 30, 2026 was 89.6%. For fiscal 2025 it was 93.3%, against 89.6% the year before. The highest annual figure on record is 99.4% in fiscal 2018.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 93.3% | +3.7 |
| FY2024 | Dec 31, 2024 | 89.6% | −4.3 |
| FY2023 | Dec 31, 2023 | 93.9% | −4.6 |
| FY2022 | Dec 31, 2022 | 98.5% | −0.7 |
| FY2021 | Dec 31, 2021 | 99.3% | +0.1 |
| FY2020 | Dec 31, 2020 | 99.2% | +0.7 |
| FY2019 | Dec 31, 2019 | 98.5% | −0.9 |
| FY2018 | Dec 31, 2018 | 99.4% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | 86.7% | −6.5 |
| Q2 FY2026 | Jun 30, 2026 | 89.2% | −6.4 |
| Q1 FY2026 | Mar 31, 2026 | 92.2% | +0.4 |
| Q4 FY2025 | Dec 31, 2025 | 91.5% | +1.5 |
| Q3 FY2025 | Sep 30, 2025 | 93.2% | +7.7 |
| Q2 FY2025 | Jun 30, 2025 | 95.6% | +3.2 |
| Q1 FY2025 | Mar 31, 2025 | 91.7% | −1.4 |
| Q4 FY2024 | Dec 31, 2024 | 89.9% | +0.5 |
| Q3 FY2024 | Sep 30, 2024 | 85.5% | −10.0 |
| Q2 FY2024 | Jun 30, 2024 | 92.4% | −3.6 |
| Q1 FY2024 | Mar 31, 2024 | 93.1% | −3.1 |
| Q4 FY2023 | Dec 31, 2023 | 89.4% | −9.9 |
| Q3 FY2023 | Sep 30, 2023 | 95.5% | −3.4 |
| Q2 FY2023 | Jun 30, 2023 | 96.0% | −0.5 |
| Q1 FY2023 | Mar 31, 2023 | 96.3% | −3.0 |
| Q4 FY2022 | Dec 31, 2022 | 99.3% | +1.7 |
| Q3 FY2022 | Sep 30, 2022 | 98.9% | −0.4 |
| Q2 FY2022 | Jun 30, 2022 | 96.5% | −3.0 |
| Q1 FY2022 | Mar 31, 2022 | 99.3% | −0.3 |
| Q4 FY2021 | Dec 31, 2021 | 97.6% | +3.1 |
| Q3 FY2021 | Sep 30, 2021 | 99.3% | +11.5 |
| Q2 FY2021 | Jun 30, 2021 | 99.5% | +7.8 |
| Q1 FY2021 | Mar 31, 2021 | 99.6% | +77.1 |
| Q4 FY2020 | Dec 31, 2020 | 94.5% | +5.8 |
| Q3 FY2020 | Sep 30, 2020 | 87.8% | +33.1 |
| Q2 FY2020 | Jun 30, 2020 | 91.7% | −3.0 |
| Q1 FY2020 | Mar 31, 2020 | 22.5% | −40.5 |
| Q4 FY2019 | Dec 31, 2019 | 88.6% | +69.9 |
| Q3 FY2019 | Sep 30, 2019 | 54.7% | −43.9 |
| Q2 FY2019 | Jun 30, 2019 | 94.8% | −3.6 |
| Q1 FY2019 | Mar 31, 2019 | 63.0% | – |
| Q4 FY2018 | Dec 31, 2018 | 18.8% | – |
| Q3 FY2018 | Sep 30, 2018 | 98.6% | – |
| Q2 FY2018 | Jun 30, 2018 | 98.3% | – |
See a number that looks wrong?